XBiotech Announces Research Collaboration with Renowned Gastroenterologist
(Thomson Reuters ONE) -
XBiotech's True Human antibodies Targeting IL-1 alpha (IL-1alpha) to be used in
Researching Treatment for Inflammatory Bowel Disease (IBD)
AUSTIN, Texas, Nov. 17, 2016 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT),
developer of True Human(TM) therapeutic antibodies, announced today commencement
of a collaboration with a research team at Case Western Reserve University
(CWRU) School of Medicine headed by leading gastroenterologist, Fabio Cominelli,
M.D., Ph.D. Dr. Cominelli and his research team will conduct pre-clinical
studies to help develop new treatments for Inflammatory Bowel Disease (IBD)
using the company's pioneering approach to using natural human antibody therapy
to neutralize harmful inflammation. Dr. Cominelli is a world-leading expert in
inflammatory bowel disease. His group was the first to report that specific
blockade of interleukin-1 (IL-1) was effective in reducing disease severity in
colitis and that deregulated inflammation is a cause of auto-inflammatory
diseases, including IBD.
Dr. Cominelli is Chief of the Division of Gastroenterology and Liver Disease and
Director of the Digestive Health Institute at CWRU School of Medicine in
Cleveland and Chief Scientific Officer of the Digestive Health Institute at
University Hospitals Cleveland Medical Center. Dr. Cominelli is also the Hermann
Menges Jr. Chair in Internal Medicine and Professor at CWRU School of Medicine.
Dr. Cominelli has a professional interest in Crohn's disease, gastrointestinal
(GI) cancer, IBD and ulcerative colitis. He is a member of the American Society
for Clinical Investigation and Association of American Physicians. He has
previously earned a NIH Merit Award. His work has been published in a number of
peer-reviewed journals, such as Inflammatory Bowel Diseases and The Journal of
Immunology. Dr. Cominelli earned his medical degree at Universita' Degli Studi
di Firenze in Florence, Italy, where he also completed his internal medicine
residency. He completed his gastroenterology fellowship at Harbor-UCLA Medical
Center in Torrance, California.
Dr. Cominelli stated, "I have researched IL-1's role in disease severity in
colitis for many years, and am excited about the opportunity to be able to
selectively inhibit IL-1 alpha to better define its role in IBD. These results
will help shape the design of future clinical trials as we look for new and
better treatments for this wide-spread condition."
John Simard, the Company's President and Chief Executive Officer, commented,
"Dr. Cominelli's past research has formed the foundation for clinical trials
with important implications for new treatments for patients suffering from
inflammatory diseases of the bowl. We are hopeful that this collaboration will
provide for further advances in treatment."
About Inflammatory Bowel Disease
Inflammatory bowel disease (IBD) is a common condition involving chronic
inflammation of the digestive tract. IBD primarily includes ulcerative colitis
and Crohn's disease, both of which are typically associated with severe
diarrhea, pain, fatigue and weight loss. IBD can have a devastating impact on
quality of life and in some cases lead to life-threatening complications. There
are approximately 1.6 million Americans and 5 million people worldwide suffering
from IBD with as many as 70,000 new cases diagnosed yearly in the U.S(1).
About True Human(TM) Therapeutic Antibodies
Unlike previous generations of antibody therapies, XBiotech's True Human(TM)
antibodies are derived without modification from individuals who possess natural
immunity to certain diseases. With discovery and clinical programs across
multiple disease areas, XBiotech's True Human antibodies have the potential to
harness the body's natural immunity to fight disease with increased safety,
efficacy and tolerability.
About XBiotech
XBiotech is a fully integrated global biosciences company dedicated to
pioneering the discovery, development and commercialization of therapeutic
antibodies based on its True Human(TM) proprietary technology. XBiotech
currently is advancing a robust pipeline of antibody therapies to redefine the
standards of care in oncology, inflammatory conditions and infectious diseases.
Headquartered in Austin, Texas, XBiotech also is leading the development of
innovative biotech manufacturing technologies designed to more rapidly, cost-
effectively and flexibly produce new therapies urgently needed by patients
worldwide. For more information, visit www.xbiotech.com.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements, including declarations
regarding management's beliefs and expectations that involve substantial risks
and uncertainties. In some cases, you can identify forward-looking statements by
terminology such as "may," "will," "should," "would," "could," "expects,"
"plans," "contemplate," "anticipates," "believes," "estimates," "predicts,"
"projects," "intend" or "continue" or the negative of such terms or other
comparable terminology, although not all forward-looking statements contain
these identifying words. Forward-looking statements are subject to inherent
risks and uncertainties in predicting future results and conditions that could
cause the actual results to differ materially from those projected in these
forward-looking statements. These risks and uncertainties are subject to the
disclosures set forth in the "Risk Factors" section of certain of our SEC
filings. Forward-looking statements are not guarantees of future performance,
and our actual results of operations, financial condition and liquidity, and the
development of the industry in which we operate, may differ materially from the
forward-looking statements contained in this press release. Any forward-looking
statements that we make in this press release speak only as of the date of this
press release. We assume no obligation to update our forward-looking statements
whether as a result of new information, future events or otherwise, after the
date of this press release.
(1 )The Facts About Inflammatory Bowel Disease. Crohn's & Colitis Foundation of
America. November 2014.
Contact
Ashley Otero
aotero(at)xbiotech.com
512-386-2930
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: XBiotech, Inc via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 17.11.2016 - 14:00 Uhr
Sprache: Deutsch
News-ID 507844
Anzahl Zeichen: 7265
contact information:
Town:
Austin
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 220 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"XBiotech Announces Research Collaboration with Renowned Gastroenterologist"
steht unter der journalistisch-redaktionellen Verantwortung von
XBiotech, Inc (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
